Squarepoint
IONS icon

Squarepoint’s Ionis Pharmaceuticals IONS Stock Holding History

Squarepoint’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,100
Closed -$245K – 4599
2025
Q4 		$245K Sell
3,100
-53,000
-94% -$3.99M ﹤0.01% 3744
2025
Q3 		$3.67M Buy
+56,100
New +$2.74M ﹤0.01% 1646

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Squarepoint's IONS Position: Q2 2026 in Review

Squarepoint reduced its Ionis Pharmaceuticals (IONS) stake by 84% in Q2 2026, selling an estimated $44.1M and leaving 109,379 shares worth $8.67M. The position accounts for 0.01% of the portfolio, ranked #1195.

Squarepoint first reported a position in IONS in Q2 2015 and has held it in 39 quarters since. The position peaked at $52.2M in Q1 2026. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Squarepoint held 109,379 shares of Ionis Pharmaceuticals worth $8.67M as of Q2 2026.
  • Squarepoint sold 585,897 Ionis Pharmaceuticals shares in Q2 2026, an estimated $44.1M.
  • Ionis Pharmaceuticals made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1195 holding.
  • Squarepoint first reported a position in Ionis Pharmaceuticals in Q2 2015 and has held it in 39 quarters since.
  • Squarepoint's Ionis Pharmaceuticals position peaked at $52.2M in Q1 2026.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.